Alex A. Adjei

Cleveland Clinic — United States

Medicine · Health Sciences

94h-index37.8kcitations779works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(263), Lung Cancer Research Studies(107), Colorectal Cancer Treatments and Studies(97), Lung Cancer Diagnosis and Treatment(77), Cancer Genomics and Diagnostics(71)

Publications777 total

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Anti-Tumor Surveillance Activation
Clinical Cancer Research·2026
The Perils of AI-Generated Peer Review
Journal of Thoracic Oncology·2026Open Access
20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies
Journal of Thoracic Oncology·2026Open Access
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study
Lung Cancer·2025· 1 cited
Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics
Journal of Clinical Investigation·2025· 1 citedOpen Access
Is PPM1D a potential driver of myeloid malignancy transformation in neuroendocrine tumor (NET) patients: An underrecognized malignant CHIPeRpetRaTor?
Blood·2025Open Access
Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis
Blood·2025Open Access
A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations
Blood·2025Open Access
Lung Cancer in 2025: Advances in Treatment Continue, but Access Remains Unequal
Journal of Thoracic Oncology·2025
CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology·2025Open Access
Linking Entrepreneurship Education to Entrepreneurial Career Choice: The Roles of Opportunity Recognition and Individual Agency
Journal of African Business·2025
P3.18.88 Title:TUB-030, a Novel Adc: A Phase I/IIA Multi-Center, FIH Trial (5-STAR 1-01) in Patients With Advanced/Metastatic Solid Tumors
Journal of Thoracic Oncology·2025
P1.11.77 A Comprehensive Analysis of Front-Line Regimens for Stage IV Non-Squamous Non-Small Cell Lung Cancer: A 13-Year Experience
Journal of Thoracic Oncology·2025
1555P Keynote-G08: An open-label, multicenter, dose escalation and expansion phase I/II study of GI-102 (CD80/IL2v3) in advanced solid tumors (part A and D of GII-102-P101)
Annals of Oncology·2025
Where Do We Go With the Combination of Immune Checkpoint Inhibitors With Anti-Angiogenesis in Advanced NSCLC?
Journal of Thoracic Oncology·2025Open Access
AML-440: Actionable but Overlooked: Targetable Mutations in AML
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MDS-806 Genomic Insights Into Myelodysplastic Syndrome: Uncovering Understudied Mutations
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-806: Genomic Insights into Myelodysplastic Syndrome: Uncovering Understudied Mutations
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-440 Actionable but Overlooked: Targetable Mutations in AML
Clinical Lymphoma Myeloma & Leukemia·2025
Artificial Intelligence, Ghost Writers, and Scientific Integrity
Journal of Thoracic Oncology·2025· 1 citedOpen Access
page 1 of 39Next →

Frequent Co-authors

Solange Peters(12), Enriqueta Felip(9), Rolf A. Stahel(8), Martin Reck(6), Luis Paz‐Ares(6), Julian R. Molina(5), Christophe Dooms(5), Jean-Yves Douillard(5), Corinne Faivre‐Finn(5), Eric Lim(5), Gaetano Rocco(5), Suresh Senan(5), Paul Van Schil(5), Benjamin Besse(5), Wilfried Eberhardt(5), Martin J. Edelman(5), Tony Mok(5), Kenneth J. O’Byrne(5), Paul Baas(5), Konstantinos Syrigos(5)